biotech · Advanced Solid Tumors · Tumor, Solid · EIKN
Eikon Therapeutics
Eikon Therapeutics clinical programs — 10 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 230 Harriet Tubman Way, Millbrae, CA 94030, US
- Founded
- 2019
- Employees
- 404
- Programs
- 15
- Drugs
- 13
- Patents
- 4
Eikon Therapeutics projects
10 ClinicalTrials.gov programs sponsored by Eikon Therapeutics.
Eikon Therapeutics has 10 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Association atezolizumab + BDB001 + RT
Eikon Therapeutics
Solid Tumor, Adult
1 trial -
BDB001
Eikon Therapeutics
Tumor, Solid
1 trial -
EIK1001
Eikon Therapeutics
NSCLC
1 trial -
EIK1001-008
Eikon Therapeutics
Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)
1 trial -
EIK1003-001
Eikon Therapeutics
Advance solid tumors
1 trial -
EIK1004 20mg Tablets, EIK1004 5mg Tablets
Eikon Therapeutics
Advanced solid tumors
1 trial -
EIK1004-001 (IMP1707-001)
Eikon Therapeutics
Advanced Solid Tumors
1 trial -
EIK1005
Eikon Therapeutics
Advanced Solid Tumors
1 trial -
EIK1005-002
Eikon Therapeutics
Advanced Solid Tumors
1 trial -
IMP1734
Eikon Therapeutics
Advanced Solid Tumor
1 trial
Frequently asked questions
How many clinical projects does Eikon Therapeutics have?
10 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.